TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04528823

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strategy 2: Symptom screen, Genexpert and TST
Description: Participants follow an algorithm similar to the standard care, however participants with positive symptom screen and/or positive TST will receive GX (i.e., GX replaces CXR in standard care algorithm). GX positive are considered to have active TB. TST positive and GX negative receive LTBI treatment. If an individual is not able to provide sputum, they will undergo a CXR.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strategy 3:Symptom screen, CXR but NO TST
Description: Participants will receive symptom screening and CXR. No TST will be performed. If CXR abnormal or symptom positive, they undergo microbiological investigation. If the CXR is normal, and/or microbiological investigations negative - they receive LTBI treatment as per national guidelines. If microbiological investigation is positive they will be offered treatment for active TB.
Study: NCT05679999

Intervention type: DIAGNOSTIC_TEST
Intervention: CIMT (Carotid artery intima media thickness measurement)
Description: Carotid artery intima media thickness measurement with ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: CIMT (Carotid artery intima media thickness measurement)
Description: Carotid artery intima media thickness measurement with ultrasound
Study: NCT01667406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 1.6nmol/kg
Description: single kisspeptin dose 1.6 nmol/kg subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 3.2nmol/kg
Description: single kisspeptin dose 3.2 nmol/kg subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 3.2nmol/kg
Description: single kisspeptin dose 3.2 nmol/kg subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 6.4nmol/kg
Description: single kisspeptin dose 6.4 nmol/kg subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 6.4nmol/kg
Description: single kisspeptin dose 6.4 nmol/kg subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 9.6nmol/kg
Description: single kisspeptin dose 9.6 nmol/kg subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 12.8nmol/kg
Description: single kisspeptin dose 12.8 nmol/kg subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 12.8nmol/kg
Description: single kisspeptin dose 12.8 nmol/kg subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 9.6 nmol/kg double
Description: kisspeptin dose 9.6 nmol/kg given twice 10hrs apart subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin 9.6 nmol/kg + saline
Description: kisspeptin dose 9.6 nmol/kg subcutaneously and saline subcutaneously, 10hrs apart
Study: NCT01759147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment of acromioclavicular dislocation.
Description: Coracoclavicular ligament repair using autogenous gracilis tendon implanted using an endobutton system containing fibrewires and a single transclavicular, transcoracoid bone tunnel.
Study: NCT00916305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Audio video
Description: An audio video modified to mimic noise induced hearing loss after one night at a loud club

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unmodified audio video
Description: An audio video with unaltered music
Study: NCT00943787

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hyperinsulinemic, euglycemic and hypoglycemic clamp
Description: At 21:30h, an overnight insulin infusion was titrated to control the subjects' BG overnight between 100 and 150mg/dL by blood sampling for plasma glucose via a YSI analyzer every 30min and adjusting the rate of insulin infusion as needed. At the beginning of the clamp, the overnight insulin was replaced by an insulin infusion via a Harvard pump given as a 20mU/kg priming over a 10-min period, followed by a constant rate delivery of 1mU/kg/min until the end of the clamp. Blood was sampled for plasma glucose, and glucose was clamped at basal levels for the euglycemic control period of 150min via a variable-rate infusion of 20% dextrose. Then the glucose concentration was lowered at a rate of 1mg/dL/min to a minimum of 50mg/dL, where it was held constant for 30min. Finally, the glucose concentration was increased at a rate of 1mg/dL/min to 90mg/dL, where it was held for an additional 30min. Blood was sampled for epinephrine during euglycemia, hypoglycemia, and recovery.
Study: NCT02453243

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Safety Planning
Description: Suicide screen-positive patients who are to be discharged from the ED will receive personalized safety planning by a mental health clinician or nurse

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A Lean Implementation Strategy
Description: The Safety Planning Intervention will be implemented using Lean performance improvement strategies.~Sites will be trained on the Safety Planning Intervention and Lean.
Study: NCT02520700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daylight and Maquet Power 500 LED surgery light
Description: Comparing the use of daylight and a surgical light (Maquet Power 500 LED surgery light) to activate ALA cream for treatment of actinic keratoses
Study: NCT01233661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: short AVD pacing ; prior (stable) programming
Description: short AVD pacing prior (stable) programming
Study: NCT03815253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Body electro-acupuncture will choose eight acupoints as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), Sanyinjiao(SP-6).Disposable acupuncture needles (verum acupuncture needles asia-med Special No. 16 with 0.30 x 0.30mm matching the Streitberger sham-needles) will be inserted at a depth of 10-25 mm into the points.~We will also deliver electrical stimulation with dense-disperse waves with 50Hz at 10 volts through electrical acupuncture stimulation instrument (ES-160 6-Channel Programmable Electro-acupuncture) to the abdominal points. The bodily needles will be retained for 30 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: acupuncture
Description: Body electro-acupuncture will choose eight acupoints as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), Sanyinjiao(SP-6).Disposable acupuncture needles (verum acupuncture needles asia-med Special No. 16 with 0.30 x 0.30mm matching the Streitberger sham-needles) will be inserted at a depth of 10-25 mm into the points.~We will also deliver electrical stimulation with dense-disperse waves with 50Hz at 10 volts through electrical acupuncture stimulation instrument (ES-160 6-Channel Programmable Electro-acupuncture) to the abdominal points. The bodily needles will be retained for 30 minutes.
Study: NCT01359839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response and Cognitive Behavioral Therapy
Description: This is a group format which will meet once per week and teach the techniques of cognitive behavioral therapy as well as relaxation response meditation.
Study: NCT02229227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide
Description: Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine and Insulin Lispro
Description: Insulin glargine and insulin lispro will be provided as injection pens for SC injection
Study: NCT02171884

Intervention type: OTHER
Intervention: Sample of cord blood

Intervention type: OTHER
Intervention: Sample of cord blood

Intervention type: OTHER
Intervention: Sample of cord blood

Intervention type: OTHER
Intervention: Sample of cord blood

Intervention type: OTHER
Intervention: Sample of placenta

Intervention type: OTHER
Intervention: Sample of placenta

Intervention type: OTHER
Intervention: Sample of placenta
Study: NCT00160342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esterified Estrogens (EE) and Methyltestosterone (MT)
Description: oral tablet, QD, 12 weeks, 0.60 MT
Study: NCT02171884

Intervention type: OTHER
Intervention: Sample of placenta
Study: NCT00293345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Study: NCT00637468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous injection of heparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous injection of heparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous injection of acetazolamide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local intra-arterial fibrinolysis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Globe massage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical use of beta-blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isovolaemic haemodilution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Study: NCT02582268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intrauterine device TCu 380A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intrauterine device TCu 380A

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Trans-abdominal sonography
Study: NCT00751322

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RBC transfusion of 5 days or less storage age
Description: RBC transfusion of 5 days or less storage age

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RBC transfusion of conventional storage age
Description: RBC transfusion of conventional storage age
Study: NCT00415701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: Single induction dose of etomidate 0.2%; total dose 0.15 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Single induction dose of propofol 2%; total dose 1.5 mg/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrocortisone
Description: Hydrocortisone 100 mg/2 ml: day of operation 3x, POD 1 2x, POD 2 1x

Intervention type: DRUG
Group type: OTHER
Intervention: NaCl 0.9%
Description: NaCl 0.9% 2 ml; day of operation 3x, POD 1 2x, POD 2 1x

Intervention type: OTHER
Group type: OTHER
Intervention: Tetracosactin
Description: Diagnostic test, Tetracosactin 250 microg iv
Study: NCT01477580

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose V180 with low-dose ISCOMATRIX™ adjuvant
Description: Three 0.5-mL intramuscular doses of low-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant
Description: Three 0.5-mL intramuscular doses of low-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium-dose V180 (non-adjuvanted)
Description: Three 0.5-mL intramuscular doses of medium-dose V180 with no adjuvant at Months 0, 1, and 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant
Description: Three 0.5-mL intramuscular doses of medium-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant
Description: Three 0.5-mL intramuscular doses of medium-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium-dose V180 with Alhydrogel™ adjuvant
Description: Three 0.5-mL intramuscular doses of medium-dose V180 containing Alhydrogel™ adjuvant at Months 0, 1, and 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose V180 (non-adjuvanted)
Description: Three 0.5-mL intramuscular doses of high-dose V180 with no adjuvant at Months 0, 1, and 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose V180 with low-dose ISCOMATRIX™ adjuvant
Description: Three 0.5-mL intramuscular doses of high-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose V180 with medium-dose ISCOMATRIX™ adjuvant
Description: Three 0.5-mL intramuscular doses of high-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose V180 with high-dose ISCOMATRIX™ adjuvant
Description: Three 0.5-mL intramuscular doses of low-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant
Description: Three 0.5-mL intramuscular doses of medium-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose V180 with high-dose ISCOMATRIX™ adjuvant
Description: Three 0.5-mL intramuscular doses of high-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three 0.5-mL intramuscular doses of phosphate-buffered saline at Months 0, 1, and 2
Study: NCT00160342

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esterified Estrogens (EE) and Methyltestosterone (MT)
Description: oral tablet, QD, 12 weeks, Placebo
Study: NCT04521842

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip replacement
Description: Total hip replacement in treatment of end-stage osteoarthritis

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Total hip replacement
Description: Total hip replacement in treatment of end-stage osteoarthritis
Study: NCT02331784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-based Software
Description: Participants will be asked to use their assigned training program for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available Video Game
Description: Participants will be asked to use their assigned video games for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
Study: NCT00963846

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching pill placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: huperzine 0.2 mg BID
Description: huperzine rising doses up to 0.2 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: huperzine 0.4 mg BID
Description: huperzine rising doses up to 0.4 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: huperzine 0.8 mg BID
Description: huperzine rising doses up to 0.8 mg BID
Study: NCT00797940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-4PE
Description: Subjects will receive intratumoral infusion of PRX321 administered via convection-enhanced delivery (CED) at a concentration of 1.5 μg/mL and a total volume of 60 mL over 2 to 7 days.
Study: NCT03260114

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personal Activity Intelligence
Description: Participants randomized to the PAI eHealth program will be given a Mio Slice wristband (http://www.mioglobal.com/pai/), to measure the heart rate for calculating PAI. A weekly PAI of 100 can be achieved by a combination of different exercise intensities and the participants will, at any time, get information from the device (Mio Slice) (and the PAI App if they chose to use that as well) regarding how many minutes at specified heart rates is needed to achieve the weekly goal of 100 PAI. Participants will receive automatic feedback on a daily basis, and data will be automatically recorded on a secured server.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personal Activity Intelligence
Description: Participants randomized to the PAI eHealth program will be given a Mio Slice wristband (http://www.mioglobal.com/pai/), to measure the heart rate for calculating PAI. A weekly PAI of 100 can be achieved by a combination of different exercise intensities and the participants will, at any time, get information from the device (Mio Slice) (and the PAI App if they chose to use that as well) regarding how many minutes at specified heart rates is needed to achieve the weekly goal of 100 PAI. Participants will receive automatic feedback on a daily basis, and data will be automatically recorded on a secured server.
Study: NCT02151214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Description: Administration of standard intravenous nutritional products. The products are commonly used in the department where the research is conducted
Study: NCT04409977

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI examination
Description: Patient will be scanned in the MRI twice, once at noon (+/- 1 hour), once at 1 a.m. (+/- 1 hour). The investigators will search for any changes in functional connectivity, particular regarding the connection between the hypothalamus and pain-processing networks.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI examination
Description: Patient will be scanned in the MRI twice, once at noon (+/- 1 hour), once at 1 a.m. (+/- 1 hour). The investigators will search for any changes in functional connectivity, particular regarding the connection between the hypothalamus and pain-processing networks.
Study: NCT00642603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5 mg/kg taken intravenously on Day 1 of each 2 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5 mg/kg taken intravenously on Day 1 of each 2 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 135 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
Study: NCT01986296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Transcranial MRgFUS System
Description: Treatment with the ExAblate Transcranial MRgFUS System.
Study: NCT04375267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-TATE + olaparib
Description: 177Lu-DOTA-TATE in four cycles in combination with escalated doses of olaparib
Study: NCT01122459

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluid administration
Description: 1.5mls/kg/hr fasting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluid administration
Description: 1.5mls/kg/hr fasting
Study: NCT01268189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen diffusing dressing
Description: Oxygen diffusing dressing applied to study wound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of care dressing
Description: Xeroform control dressing applied to control wound
Study: NCT05933785

Intervention type: PROCEDURE
Intervention: transanal endoscopic ISR
Description: perform ISR using laparoscopy through transanal port
Study: NCT01893047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: live music
Description: live harp music

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: recorded music
Description: recorded harp music
Study: NCT02395419

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orotracheal intubation with Totaltrack

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orotracheal intubation with Airtraq
Study: NCT00167232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone
Study: NCT01928238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive neurally adjusted ventilatory assist (NIV-NAVA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive neurally adjusted ventilatory assist (NIV-NAVA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive pressure support ventilation (NPSV)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive pressure support ventilation (NPSV)
Study: NCT03340467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM patch
Description: Patient receives four CGM patches.
Study: NCT03298308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial Electric Stimulation
Description: Micro amperage TCDS
Study: NCT02815150

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: preoperative oral carbohydrate drink
Description: 5% glucose solution 250ml 2-3 hours before surgery
Study: NCT01646385

Intervention type: DRUG
Intervention: etanercept
Description: use as per routine clinical practice

Intervention type: DRUG
Intervention: non-biologic anti-rheumatic drugs
Description: use as per routine clinical practice (methotrexate, azathioprine, cyclophosphamide, cyclosporine, leflunomide, other)
Study: NCT04471545

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pectoral nerve block type II
Description: A pectoral nerve block type II will be given to the patient after induction. This is performed ultrasound guided

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoral nerve block type II
Description: A pectoral nerve block type II will be given to the patient after induction. This is performed ultrasound guided